Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia.
CONCLUSION: Dutasteride 0.5 mg is to be well-tolerated in 18 to 41 years old AGA patients in a clinical practice environment.
PMID: 27489426 [PubMed]
Source: Annals of Dermatology - Category: Dermatology Tags: Ann Dermatol Source Type: research
More News: Alopecia | Appendicitis | Avodart | Dermatology | Drugs & Pharmacology | Dyspepsia | Environmental Health | Gynecomastia | Impotence | Influenza | Orthopaedics | Skin | Study | Tonsillitis